APP Pharmaceuticals Named NOVAPLUS® Pharmacy Manufacturer of the Year

SCHAUMBURG, Ill.--(BUSINESS WIRE)-- APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., has been named NOVAPLUS® Pharmacy Manufacturer of the Year by Novation, the industry’s leading supply contracting company. This prestigious award recognizes APP’s ability to provide Novation’s members access to critical drugs, including those affected by market-wide shortages.

“APP Pharmaceuticals is honored to receive the NOVAPLUS Pharmacy Manufacturer of the Year Award from such a valued customer,” said John Ducker, President and Chief Executive Officer of APP Pharmaceuticals. “Throughout the year, our team has worked hard to supply Novation’s members with several critically needed drugs. This award not only recognizes the company’s efforts, but those of each APP employee and their commitment to meeting our customers’ expectations.”

Scott Meacham, Executive Vice President and Chief Commercial Officer, APP Pharmaceuticals, added, “Our most important goal is to support the needs of our customers by providing them a broad portfolio of drugs. By doing so, we are able to impact the lives of the patients they treat.”

“APP Pharmaceuticals received the NOVAPLUS Pharmacy Manufacturer of the Year Award in recognition of their exceptional support and commitment toward helping Novation members achieve their supply chain goals,” explained Pete Allen, Senior Vice President, Sourcing Operations, Novation. “APP Pharmaceuticals has truly exemplified the attributes set forth in the award criteria.”

The award was presented to APP Pharmaceuticals at the Novation Supplier Executive Forum.

About APP Pharmaceuticals, Inc.

APP Pharmaceuticals, Inc. is a fully-integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. The company offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. Fresenius Kabi Pharmaceuticals Holding, Inc., a wholly owned subsidiary of Fresenius Kabi AG, acquired APP Pharmaceuticals, Inc. on September 10, 2008. For more information about APP Pharmaceuticals, Inc., please visit the company’s Web site at www.APPpharma.com.

About Fresenius Kabi AG

Fresenius Kabi AG is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Fresenius Kabi’s core product range includes infusion solutions, blood volume substitutes, I.V. drugs and parenteral nutrition, as well as products for enteral nutrition. Furthermore, the company provides concepts for ambulatory health care and is focused on managing and providing home therapies. With the philosophy “caring for life” and a comprehensive product portfolio, the company aims at improving the quality of life of critically and chronically ill patients all over the world. In 2010, Fresenius Kabi achieved sales of EUR 3,672 million and an operating profit of EUR 737 million. For more information visit the company’s Web site at www.fresenius-kabi.com. Fresenius Kabi AG is a 100% subsidiary of Fresenius SE & Co. KGaA.

About Novation

Founded in 1998, Novation is the leading health care supply contracting company for more than 25,000 members of VHA Inc. and the University HealthSystem Consortium (UHC), two national health care alliances, and 5,500 members of Provista, LLC, representing more than 30,000 sites. Novation provides alliance members sourcing and information and data services. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 600 suppliers. VHA, UHC and Provista members used Novation contracts to purchase nearly $40 billion in 2010.

Forward-Looking Statement

The statements contained in this news release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this news release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the demand, supply and distribution of our products. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, the availability and pricing of ingredients used in the manufacture of pharmaceutical products and the ability to successfully manufacture products in a time-sensitive and cost effective manner. Additional relevant information concerning risks can be found in the Fresenius Kabi Pharmaceuticals Holding, Inc. 10-K for the fiscal year ending December 31, 2010 and other documents the company has filed with the Securities and Exchange Commission.

The information contained in this news release is as of the date of this release. Fresenius Kabi Pharmaceuticals Holding, Inc. does not assume any obligation to update or revise these forward-looking statements to conform the statement to actual results, new information, developments or changes in the Company’s expectations.



CONTACT:

APP Pharmaceuticals, Inc.
Debra Lynn Ross, ABC
Director, Corporate Communications
847-969-8026
[email protected]

KEYWORDS:   United States  Europe  North America  Illinois

INDUSTRY KEYWORDS:   Surgery  Health  Biotechnology  Hospitals  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.